Related Experiment Video
Updated: Feb 24, 2026
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression
Jin Woo Choi1, Hyungbeen Lee2, Gyudo Lee3
1Laboratory of Pharmacogenetics, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
Abstract:
Matrix metalloproteinase (MMP) is a key marker and target molecule for cancer diagnosis, as MMP is able to cleave peptide chains resulting in degradation of extracellular matrix (ECM), a necessary step for cancer development. In particular, MMP2 has recently been recognized as an important biomarker for lung cancer. Despite the important role of detecting MMP molecules in cancer diagnosis, it is a daunting task to quantitatively understand a correlation between the status of cancer development and the secretion level of MMP in a blood droplet. Here, we demonstrate a nanoscale cancer diagnosis by nanomechanical quantitation of MMP2 molecules under cancer progression with using a blood droplet of lung cancer patients. Specifically, we measured the frequency dynamics of nanomechanical biosensor functionalized with peptide chains mimicking ECM in response to MMP2 secreted from tumors in lung with different metastasis level. It is shown that the frequency shift of the biosensor, which exhibits the detection sensitivity below 1 nM, enables the quantitation of the secretion level of MMP2 molecules during the progression of cancer cells or tumor growth. More importantly, using a blood droplet of lung cancer patients, nanomechanical biosensor is shown to be capable of depicting the correlation between the secretion level of MMP2 molecules and the level of cancer metastasis, which highlights the cantilever-based MMP2 detection for diagnosis of lung cancer. Our finding will broaden the understanding of cancer development activated by MMP and allow for a fast and point-of-care cancer diagnostics.
Insights
This study presents a nanoscale method for lung cancer diagnosis by quantifying matrix metalloproteinase 2 (MMP2) in blood droplets. The nanomechanical biosensor accurately correlates MMP2 levels with cancer progression and metastasis.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Matrix metalloproteinases (MMPs), particularly MMP2, are crucial biomarkers in cancer development and progression.
- Accurate quantification of MMP levels in patient blood is essential for understanding cancer status but remains challenging.
- MMP2's role in extracellular matrix degradation is vital for tumor growth and metastasis.
Purpose of the Study:
- To develop a nanomechanical biosensor for quantifying MMP2 levels in lung cancer patients.
- To establish a correlation between MMP2 secretion levels and the extent of lung cancer metastasis.
- To enable fast, point-of-care diagnosis of lung cancer using a blood droplet.
Main Methods:
- Utilized a nanomechanical biosensor functionalized with ECM-mimicking peptide chains.
- Measured frequency dynamics of the biosensor in response to MMP2.
- Quantified MMP2 levels in blood droplets from lung cancer patients with varying metastasis.
- Achieved detection sensitivity below 1 nM for MMP2.
Main Results:
- Demonstrated nanomechanical quantitation of MMP2 in lung cancer patient blood.
- Established a correlation between MMP2 secretion levels and cancer metastasis.
- Biosensor exhibited high sensitivity (<1 nM) for MMP2 detection.
- Successfully depicted the relationship between MMP2 levels and cancer progression.
Conclusions:
- Nanomechanical biosensor enables accurate, quantitative detection of MMP2 in lung cancer patients.
- The technology provides a sensitive method for correlating MMP2 levels with cancer metastasis.
- This approach offers potential for fast, point-of-care lung cancer diagnostics.
